Welcome to our dedicated page for Wave Life Scienc news (Ticker: WVE), a resource for investors and traders seeking the latest updates and insights on Wave Life Scienc stock.
Wave Life Sciences Ltd. develops RNA medicines as a clinical-stage biotechnology company, using its PRISM platform to design oligonucleotides across RNA editing, RNA interference and antisense silencing. Company news commonly centers on clinical and regulatory updates for investigational programs such as WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for alpha-1 antitrypsin deficiency, and WVE-007, an INHBE GalNAc-siRNA evaluated for obesity and cardiometabolic disease biology.
Updates also cover financial results, corporate presentations, platform expansion, collaboration activity involving PRISM, and governance or capital-structure matters. Recurring scientific disclosures include trial data presentations, safety and tolerability findings, regulatory engagement, and pipeline work in liver, muscle and neurologic diseases.
Wave Life Sciences (Nasdaq: WVE) has announced a virtual Research Day on October 30, 2024, from 10:00 a.m. to 11:30 a.m. ET. The event will showcase the company's progress in RNA medicines, including:
- Updates on their wholly owned pipeline
- Introduction of new GalNAc-conjugated RNA editing and siRNA programs
- Discussion of their clinically validated discovery and drug development platform
The company will highlight WVE-006, their RNA editing oligonucleotide for alpha-1 antitrypsin deficiency (AATD), and WVE-007, a GalNAc-siRNA INHBE candidate for obesity treatment. Dr. Mehmet Furkan Burak, an obesity specialist from Harvard Medical School, will provide insights on the current obesity treatment landscape. The event will be accessible via webcast on Wave Life Sciences' investor relations website.
Wave Life Sciences (Nasdaq: WVE) has successfully closed its previously announced public offering, raising approximately $230 million in gross proceeds. The offering included 26,875,001 ordinary shares at $8.00 per share and pre-funded warrants to purchase 1,875,023 ordinary shares. The underwriters fully exercised their option to purchase an additional 3,750,000 ordinary shares at the same price. J.P. Morgan and Leerink Partners served as joint book-running managers, with Truist Securities and Mizuho as book-runners. The offering was made through a shelf registration statement filed with the SEC, with the final prospectus supplement and accompanying base prospectus available on the SEC's website.
Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focusing on RNA medicines, has announced its participation in the Chardan 8th Annual Genetic Medicines Conference in New York City. Paul Bolno, MD, MBA, the company's President and CEO, is scheduled for an analyst-led fireside chat on Tuesday, October 1, 2024, at 1:00 p.m. ET.
The presentation will be accessible via a live webcast on the Investor Relations page of Wave Life Sciences' website. A replay will be available for a time after the event. This conference appearance underscores Wave Life Sciences' commitment to advancing RNA medicines and engaging with the investment community.
Wave Life Sciences (Nasdaq: WVE) has announced the pricing of its upsized public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $200 million in gross proceeds. The offering includes 23,125,001 ordinary shares at $8.00 per share and pre-funded warrants to purchase up to 1,875,023 ordinary shares at $7.9999 per warrant. The company has also granted underwriters a 30-day option to purchase up to an additional 3,750,000 ordinary shares. The offering is expected to close around September 27, 2024. J.P. Morgan and Leerink Partners are acting as joint book-running managers, with Truist Securities and Mizuho as book-runners. The offering is being made through a prospectus and related supplement, with details available on the SEC's website.
Wave Life Sciences (Nasdaq: WVE) has announced a proposed public offering of $175 million in ordinary shares and pre-funded warrants. The biotechnology company, focused on RNA medicines, intends to grant underwriters a 30-day option to purchase additional ordinary shares up to 15% of the total offering. J.P. Morgan and Leerink Partners are acting as joint book-running managers, with Truist Securities and Mizuho as book-runners.
The offering is subject to market conditions and will be made through a prospectus and related supplement. A preliminary prospectus supplement and accompanying base prospectus will be filed with the SEC and available on their website. The final terms will be disclosed in a final prospectus supplement.
Wave Life Sciences announced positive interim data from the FORWARD-53 clinical trial evaluating WVE-N531 in boys with Duchenne Muscular Dystrophy (DMD) amenable to exon 53 skipping. Key findings include:
- Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%
- Meaningful improvement in serum biomarkers for muscle health
- Skeletal muscle concentrations of ~41,000 ng/g with 61-day tissue half-life
- WVE-N531 was safe and well-tolerated with only mild treatment-related adverse events
The company expects feedback on a pathway to accelerated approval and complete 48-week data in Q1 2025. Wave Life Sciences is advancing a broader DMD pipeline targeting up to 40% of boys with DMD.
Wave Life Sciences (Nasdaq: WVE) has received FDA Rare Pediatric Disease Designation for WVE-N531, a treatment for Duchenne muscular dystrophy (DMD) patients amenable to exon 53 skipping. The company expects to deliver data from the potentially registrational FORWARD-53 trial, including dystrophin protein expression, in Q3 2024.
In a previous Part A study, WVE-N531 achieved 53% exon skipping and muscle tissue concentrations 20-30 times higher than those reported by technologies using muscle delivery conjugates. The treatment also demonstrated distribution to myogenic stem cells, a unique feature among exon skipping therapies. Preclinical data showed potential for cardiac and respiratory benefits.
Wave Life Sciences (Nasdaq: WVE) reported Q2 2024 financial results and provided a business update. Key highlights include:
1. Successful clinical translation of RNA medicines platform in HD patients with WVE-003, showing statistically significant mHTT reductions up to 46%.
2. Dystrophin data expected in Q3 2024 from FORWARD-53 trial of WVE-N531 for DMD.
3. Dosing initiated in RestorAATion-2 trial of WVE-006 for AATD; proof-of-mechanism data expected in Q4 2024.
4. New preclinical data on WVE-007 for obesity expected at R&D Day in Fall 2024.
5. Q2 2024 revenue: $19.7 million; net loss: $32.9 million.
6. Cash position: $154.0 million as of June 30, 2024, expected to fund operations into Q4 2025.
Wave Life Sciences (Nasdaq: WVE), a clinical-stage biotechnology company focusing on RNA medicines, has announced its upcoming second quarter 2024 financial results release. The company will host a live webcast and conference call on Thursday, August 8, 2024, at 8:30 a.m. ET to discuss the results and provide business updates.
Investors and interested parties can access the webcast through the 'Investor Events' section of the company's website. Analysts wishing to participate in the Q&A session can join via a provided audio conferencing link. An archived version of the webcast will be available on the company's website following the live event.
Wave Life Sciences announced positive results from their Phase 1b/2a SELECT-HD trial for WVE-003, a therapeutic for Huntington's disease (HD). The trial showed a statistically significant 46% reduction in mutant huntingtin (mHTT) protein in the cerebrospinal fluid compared to placebo, while preserving wild-type huntingtin (wtHTT) protein. The drug was generally safe and well-tolerated. These results validate Wave's RNA medicines platform and support potential accelerated approval discussions with regulators. Wave plans to continue developing WVE-003 and other therapies targeting HD and other conditions, with anticipated data releases in 2024 and 2025.